Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure
Andrea Vittorini
Zenodo (CERN European Organization for Nuclear Research) September 27, 2026 preprint DOI: 10.5281/zenodo.23001108 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Randomized |
|---|---|
| Intervention | Psilocybin |
| Dose | 2 mg psilocybin once weekly |
| Topics | Microdosing Psilocybin Serotonin |
| Key points | Argues that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research, because existing controlled studies have predominantly used intermittent schedules and the first dedicated randomized trial in major depressive disorder (2 mg psilocybin once weekly) did not demonstrate superiority over placebo, leaving continuous daily exposure and the hypothesized receptor-adaptation state inadequately tested. Proposes falsifiable schedule-by-age/cortical-state predictions and research designs comparing continuous, intermittent, and low-frequency exposure. |
Abstract
This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate superiority over placebo, leaving continuous daily exposure and the receptor-adaptation state hypothesized to arise from limited inter-dose recovery inadequately tested. The article extends a previous 5-HT2A receptor-adaptation hypothesis by integrating: (1) regulated and late-stage clinical psilocybin protocols; (2) controlled and naturalistic microdosing schedules; (3) evidence for age-associated differences in cortical 5-HT2A receptor availability; (4) cell-type-specific mechanisms implicated in persistent psilocybin effects; and (5) the 2026 lifespan single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex. It proposes falsifiable schedule-by-age/cortical-state predictions and research designs comparing continuous, intermittent and low-frequency exposure while separating subjective tolerance, receptor adaptation and persistent downstream effects. The framework is a research hypothesis. It does not establish that daily or continuous psilocybin microdosing is effective or safe and does not constitute a clinical dosing recommendation.
Comparable studies
Other theoretical and historical papers on psilocybin and microdosing, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Set and setting in microdosing: an oft-overlooked principle. | 2022 | Theoretical or philosophical paper | |
| Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis | 2026 | Theoretical or philosophical paper | |
| Microdosing psychedelics: More questions than answers? An overview and suggestions for future research | 2019 | Theoretical or philosophical paper |